Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $66.6667.

A number of brokerages recently issued reports on RVPH. Wall Street Zen cut Reviva Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Maxim Group cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, D. Boral Capital cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of RVPH. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 1st quarter valued at about $58,000. Geode Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after acquiring an additional 29,063 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter valued at about $31,000. Armistice Capital LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter valued at about $1,026,000. Finally, Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH opened at $0.67 on Friday. The stock’s 50-day simple moving average is $0.66 and its 200 day simple moving average is $3.69. The stock has a market capitalization of $8.79 million, a price-to-earnings ratio of -0.17 and a beta of 0.56. Reviva Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $17.20.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, research analysts forecast that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.